US Patent

US11661604 — Methods and compositions for inhibiting expression of LDHA

Method of Use · Assigned to Dicerna Pharmaceuticals Inc · Expires 2038-10-12 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for reducing the expression of LDHA, particularly in liver cells, using oligonucleotides.

USPTO Abstract

This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.

Drugs covered by this patent

nedosiran-sodium (NEDOSIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3709`	—	nedosiran-sodium
`U-3709`	—	nedosiran-sodium
`U-3709`	—	nedosiran-sodium

Patent Metadata

Patent number: US11661604
Jurisdiction: US
Classification: Method of Use
Expires: 2038-10-12
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dicerna Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.